Table 2.
Dosing, consumption and bleeding rates with rIX-FP prophylaxis and prior FIX product prophylaxis in patients with haemophilia B in Italy, Belgium and the UK
| Italy | Belgium | UK | ||||
|---|---|---|---|---|---|---|
| rIX-FP (n = 44) | Prior FIX (n = 44) | rIX-FP (n = 7) | Prior FIX (n = 7) | rIX-FP (n = 22) | Prior FIX (n = 22) | |
| Dose, IU/kg/week | 38.6 ± 16.5 | 84.4 ± 34.4 | 30.3 ± 11.5 | 103.1 ± 60.9 | 29.2 ± 8.5 | 71.7 ± 18.9 |
| ABR | 0.2 ± 0.4 | 3.5 ± 5.7 | 0.4 ± 0.8 | 6.6 ± 3.4 | 1.0 ± 0.9 | 3.1 ± 1.4 |
| AsBR | 0.02 ± 0.2 | 0.7 ± 1.0 | 0.0 ± 0.0 | 3.0 ± 3.3 | 0.4 ± 0.6 | 2.0 ± 1.5 |
| Patients with zero bleeds, % | 84.1 | 13.6 | 71.4 | 14.3 | 36.4 | 0.0 |
| Patients with zero spontaneous bleeds, % | 97.7 | 50.0 | 100.0 | 42.9 | 63.6 | 22.7 |
Data are presented as mean ± SD unless otherwise stated
ABR, annualised bleeding rate; AsBR, annualised spontaneous bleeding rate; SD, standard deviation